Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs

American Journal of Medicine

Volumn 104, Issue 5, 1998, Pages 413-421

  Cryer, Byron ^a,b   Feldman, Mark ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; LIPOPOLYSACCHARIDE; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN DERIVATIVE;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DIGESTIVE SYSTEM ULCER; DRUG POTENCY; ENZYME SPECIFICITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH BIOPSY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GASTRIC JUICE; GASTRIC MUCOSA; HUMANS; ISOMERISM; MALE; MIDDLE AGED; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0032076219     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00091-6     Document Type: Article

References (42)

1. 1. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci. 1991;88:2692-2696.
2. 2. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-12872.
3. 2 synthase-1. Nature. 1994;367: 243-249.
4. 4. DeWitt DL, Meade EA, Smith WL. Prostaglandin H synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med. 1993;95:40S-46S.
5. 5. Meade EA, Smith WL, DeWitt DL. Expression of the murine prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes in COX-1 cells. J Lipid Mediators. 1993;6:119-129.
6. 6. Williams CS, Dubois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270:G393-400.
7. 7. Morita I, Schindler M, Reginaler MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995;270:10902-10908.
8. 8. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482.
9. 9. Hempel SL, Monick MM, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest. 1994;93: 391-396.
10. 10. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445-454.
11. 11. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-1280.
12. 12. Chan C, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1995;274: 1531-1537.
13. 13. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
14. 14. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
15. 15. Glaser K, Sung M, O'Neil K. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (prostaglandin HS-2) versus human prostaglandin HS-1. Eur J Pharm. 1995;281:107-11.
16. 16. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci. 1994;90:11693-11697.
17. 17. Laneuville O, Breuer DK, DeWitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271: 927-934.
18. 18. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
19. 19. Brideau C, Kargman S, Liu S, Dallob AL. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res. 1996;45:68-74.
20. 20. Lee M, Feldman M. Nonessential role of leukotrienes as mediators of acute gastric mucosal injury induced by aspirin in rats. Dig Dis Sci. 1992;37:1282-1287.
21. 21. Redfern JS, Lee E, Feldman M. Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage. Gastroenterology. 1987;92:969-977.
22. 22. Colton T. Statistics in Medicine. Boston, Mass: Little, Brown and Co.; 1974.
23. 23. Piper RM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
24. 24. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Co. 1997.
25. 25. Insel PA. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gillman's: The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:638-681.
26. 26. Crook PR, Willis JV, Kendall MJ, et al. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease. Eur J Clin Pharmacol. 1982;21:331-334.
27. 2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30:660-664.
28. 28. Davies EF, Avery GS. Ibuprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic disorders. Drugs. 1971;2:416-446.
29. 29. Hundal O, Rugstad HE, Husby G. Naproxen free plasma concentrations and unbound fractions in patients with osteoarthritis: relation to age, sex, efficacy, and adverse events. Therapeut Drug Monitor. 1991;13:478-484.
30. 30. Olive G, Rey E. Effect of age and disease on the pharmacokinetics of nimesulide. Drugs. 1993;46:73-78.
31. 31. Duggan DE, Hare LE, Ditzler CA. The disposition of sulindac. Clin Pharmacol Ther. 1977;21:326-335.
32. 32. Friedel HA, Todd PA. Nabumetone: a preliminary review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. Drugs. 1988;35:504-524.
33. 33. McMahon FG, Vargas R, Ryan JR, Fitts DA. Nabumetone kinetics in the young and elderly. Am J Med. 1987;83:92-95.
34. 34. DeWitt DL, El-Harith A, Kraemer SA, et al. The aspirin and hemebinding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem. 1990;265:5192-5198.
35. 35. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation regastrointestinalon. J Biol Chem. 1992;267: 12387-12392.
36. 36. Lecomte M, Laneuville O, Ji C, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269:13207-13215.
37. 37. Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology. 1990;99:1616-1621.
38. 38. Graham DY, Smith JL, Holmes GI, Davies RO. Nonsteroidal antiinflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther. 1985;38:65-70.
39. 39. Henry D, Lim LL, Garcia-Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal antiinflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
40. 40. Willkens RF. An overview of the long-term safety experience of nabumetone. Drugs. 1990;40:34-37.
41. 41. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d. or ibuprofen (IBU) 800 mg t.i.d. Gastroenterology. 1997;112:A194.
42. 42. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-5835, a novel COX-2-selective inhibitor. Gastroenterology. 1997;112:A194.